Literature DB >> 19420310

Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis.

Deborah A Cios1, William L Baker, Stephen D Sander, Olivia J Phung, Craig I Coleman.   

Abstract

PURPOSE: The effect of study-level factors on the proportion of time spent with International Normalized Ratio (INR) values inside the therapeutic range in patients treated with warfarin in the United States was evaluated.
METHODS: Studies evaluated in a previous meta-analysis were screened for potential inclusion, in addition to a systematic literature search of databases from January 2005 through February 2008. Studies were included if they (1) contained at least one warfarin dosing group that enrolled >25 patients for whom INR control was monitored for at least three weeks, (2) included only patients treated in the United States, (3) used a patient-time approach to report outcomes, and (4) reported proportion of time spent in the therapeutic INR range. Analyses included determining how study-level factors, such as study setting, year of study publication, INR interpolation method, study design, and presence of self-management, affected outcomes.
RESULTS: Twenty-four studies, including a total of 43 unique warfarin groups, were included in the analysis. Overall, patients spent 57% of their time in the therapeutic range (95% confidence interval [CI], 55-59%). Compared with anticoagulation clinics, community management resulted in less time (-13%; 95% CI, -18% to -7.9%) and prospective studies resulted in more time (7.3%; 95% CI, 1.5-13.1%) spent in the therapeutic range than retrospective studies. When studies from both the United States and Canada were included, similar results to those in the base-case analysis were seen; however, study year and interpolation method were also found to be significant modifiers of INR control.
CONCLUSION: Patients included in the meta-analysis maintained INR values within the therapeutic range 57% of the time, although the use of anticoagulation clinic services appeared to be superior to standard community care in this regard. However, patients treated in anticoagulation clinics had INR values within the therapeutic range less than two thirds of the time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420310     DOI: 10.2146/ajhp080507

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  9 in total

1.  Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.

Authors:  Sharon Liu; Alexander Singer; Finlay A McAlister; William Peeler; Balraj S Heran; Neil Drummond; Donna P Manca; G Michael Allan; Christina Korownyk; Michael R Kolber; Michelle Greiver; Scott R Garrison
Journal:  Can Fam Physician       Date:  2019-06       Impact factor: 3.275

2.  Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin.

Authors:  Lulu Iles-Shih; Judy F Collins; Jennifer L Holub; David A Lieberman
Journal:  Am J Gastroenterol       Date:  2010-08-03       Impact factor: 10.864

3.  Monitoring of international normalized ratios: comparison of community nurses with family physicians.

Authors:  Max A Levine; Wei Shao; Douglas Klein
Journal:  Can Fam Physician       Date:  2012-08       Impact factor: 3.275

4.  Rivaroxaban in atrial fibrillation.

Authors:  Mariano A Giorgi; Lucas San Miguel
Journal:  Vasc Health Risk Manag       Date:  2012-08-30

5.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

Review 6.  Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.

Authors:  Jeff R Schein; C Michael White; Winnie W Nelson; Jeffrey Kluger; Elizabeth S Mearns; Craig I Coleman
Journal:  Thromb J       Date:  2016-06-13

7.  Warfarin Use During Fecal Occult Blood Testing: A Meta-Analysis.

Authors:  Imran Ashraf; Shafaq Paracha; Saif-Ur-Rahman Paracha; Murtaza Arif; Abhishek Choudhary; Jonathan D Godfrey; Robert E Clark; Obai Abdullah; Michelle L Matteson; Srinivas R Puli; Jamal A Ibdah; Ousama Dabbagh; Matthew L Bechtold
Journal:  Gastroenterology Res       Date:  2012-03-20

8.  Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics.

Authors:  Salih Kılıç; Hatice Soner Kemal; Elif İlkay Yüce; Evrim Şimşek; Burcu Yağmur; Nuray Memişoğlu Akgül; Cahide Soydaş Çınar; Mehdi Zoghi; Cemil Gürgün
Journal:  Anatol J Cardiol       Date:  2017-11       Impact factor: 1.596

9.  Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.

Authors:  Alberto Tosetto; Cesare Manotti; Francesco Marongiu
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.